|Mr. John McDermott MBA||CEO & Director||1.15M||N/A||57|
|Mr. Robert D. Mitchell||Pres||665.26k||N/A||55|
|Mr. Vaseem Mahboob||CFO & Corp. Sec.||571.44k||N/A||48|
|Dr. Michael V. Chobotov Ph.D.||Chief Technology Officer||344.25k||N/A||56|
|Mr. John Onopchenko||Chief Operating Officer||N/A||N/A||58|
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions, which attach to the main body of its EVAR device, allowing physicians to customize it to fit the patients anatomy; and accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Endologix, Inc.’s ISS Governance QualityScore as of November 1, 2017 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 5; Compensation: 10.